Photocure ASA (PHCUF)
Photocure ASA operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Oslo, PS, NO. The stock last traded at $5.65, up 0.00% on the session, giving a market capitalisation of $150.3M. On trailing twelve-month figures it carries a trailing P/E of 16.80, a net margin of 11.6%. Its beta of 0.35 implies it has historically moved less than the broad market.
Photocure ASA, a specialty pharmaceutical company established in Oslo, Norway in 1993, focuses on the entire lifecycle of pharmaceutical products, from research and development to manufacturing, distribution, and commercialization. The company's reach extends across the Nordic countries, major European markets like Germany, France, Austria, the United Kingdom, the Netherlands, and Italy, as well as the United States. Key offerings include Hexvix/Cysview, which is used for the identification and ongoing care of bladder cancer. Additionally, Photocure is currently developing Cevira, a treatment designed for human papillomavirus (HPV) infections and precancerous lesions of the cervix. Its products are supplied to pharmaceutical wholesalers, pharmacies, and hospitals primarily through strategic licensing partnerships.
Photocure ASA is most often compared with the following Healthcare names: